Diabetes, Hypogonadism
Conditions
Keywords
hypogonadism, diabetes, visceral fat, hepatic fat, lean mass
Brief summary
The purpose of the study is to find out the effect of replacing testosterone in the form of a gel (Androgel®) on the amount of fat mass in males with low testosterone and diabetes.
Detailed description
Hypogonadism is associated with increase in fat mass, decrease in muscle mass, accelerated bone loss, decreased libido and effects on mood. Androgen replacement in this context is clearly beneficial, and numerous studies have demonstrated improvements in bone and muscle mass, reductions in body fat and improvement in insulin sensitivity, libido and mood following treatment. Testosterone replacement leads to a dose-dependent decrease in adipose tissue and increase in muscle mass and strength. The principal focus of the proposed research is to evaluate the effect of androgel on lean body mass and regional adipose tissue mass (including hepatic and visceral fat) in type 2 diabetic patients with hypogonadism, a population that is likely to benefit from a reduction in adipose tissue and an increase in muscle mass.
Interventions
DRUGTestosterone gel
Testosterone gel to be applied daily, starting does 5g.
DRUGplacebo
placebo gel apply daily
Sponsors
Solvay Pharmaceuticals
Diabetes Center of the Southwest
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)
Eligibility
Sex/Gender
MALE
Age
35 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Males with age 35-75 years inclusive. * Evidence of hypogonadism: Hypogonadism will be defined as low total testosterone (\<300 ng/dL) and low calculated free testosterone (below 6.5ng/dL; calculated using testosterone and SHBG). Testosterone levels will be measured between 8 and 10 am. Subjects who have normal total but low free testosterone levels (or vice versa) will be asked to come again after one week to have their testosterone levels re-measured. They will be included in the study in their free and total testosterone levels are low on re-measurement. * Type 2 diabetes * Hemoglobin A1c \<8.0 % * Subjects on medications for diabetes will be allowed as long as they are on stable doses of these compounds for at least 6 weeks. The dose of thiazolidinediones will have to be stable for 3 months prior to the study. The dosage of diabetic medications will not be changed during the study.
Exclusion criteria
* Coronary event or procedure (myocardial infarction, unstable angina, coronary artery bypass, surgery or coronary angioplasty) in the previous four weeks * Hepatic disease (transaminase \> 3 times normal) * Renal impairment (serum creatinine \> 1.5) * Chronic steroid therapy * Use of testosterone or other androgens (such as DHEA) in the last 3 months * Panhypopituitarism * HIV or hepatitis C * Subjects will be excluded from the study for history of prostate or breast cancer, gonadal endocrine disorders * Current or recent history of major psychiatric illness, significant uncontrolled systemic illness * Sleep apnea * History of alcoholism or substance abuse within the past year * History of taking other drugs that might interfere with the results of the study (ie, Lupron, finasteride, spironolactone, cimetidine, antiandrogens, estrogens, p450 enzyme inducers, barbiturates) * Abnormal prostate evidenced by prostatic symptoms, prostatic masses or induration on rectal examination, elevated levels of prostate specific antigen (\>4 ng/mL; subjects with PSA levels between 2.5-4 ng/mL will be permitted if prostate biopsy is negative) or positive biopsy, a urine flow rate of less than 12 mL/s, or an International Prostate Symptom Score greater than 19 * Hematocrit greater than 50% * Body weight \>300 lbs (this is the maximum weight that can be accommodated on DEXA or MRI machines. * The subject has systolic blood pressure \>170mmHg or diastolic blood pressure \>100 mmHg while on or off anti-hypertensive treatment. * Generalized skin disease that could affect the absorption of testosterone gel (ie, psoriasis); * Morning prolactin level greater than 40 mg/mL * Subjects with serum fasting triglyceride concentration \> 500 mg/dL at screening or with history of hypertriglyceridemia-induced pancreatitis. * Participation in any other concurrent clinical trial * Any other life-threatening, non-cardiac disease * Use of an investigational agent or therapeutic regimen within 30 days or 5 half-lives (which ever is longer) preceding the first dose of study medication.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean absolute change in visceral adipose tissue mass in type 2 diabetic subjects with hypogonadism after 6 months of androgel therapy. | 6 months |
Secondary
| Measure | Time frame |
|---|---|
| Mean absolute change in hepatic fat measured by NMR spectroscopy. | 6 months |
| Mean absolute change in total and regional adipose tissue mass measured by DEXA | 6 months |
| Mean absolute change in total and regional lean body mass measured by DEXA. | 6 months |
| Study the effect in type 2 diabetic subjects with hypogonadism after 6 months of androgel therapy on: | 6 months |
| Mean absolute change in hip BMC and BMD (mean of two hips) | 6 months |
| Mean absolute change in spine BMC and lumbar spine (L1-L4) BMD | 6 months |
| Mean absolute change in total body and regional (arm, leg, ribs) BMC and BMD | 6 months |
Countries
United States
Outcome results
None listed